Missing/wrong data?
Log in to edit
Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B
Author/s
author: David Cescon, Minetta C Liu, Hiroji Iwata, Kenji Tamura, Eric Winer, Rita Nanda, Deborah Card, Sherene Loi
Work details
Publication date
May 20, 2017
-
-
Language
English
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.